Oxycodone does not reliably show up on a standard opiate (OPI) immunoassay screen, because that test is built to detect morphine and codeine, not semi-synthetic opioids. Catching oxycodone use requires a dedicated OXY immunoassay, typically run at a 100 ng/mL urine cutoff, or a mass spectrometry confirmation test that specifically targets oxycodone and its metabolite oxymorphone. That gap is exactly why pain clinics, addiction treatment programs, and employers increasingly add an OXY panel to their testing configuration instead of relying on a traditional opiate screen alone.
Why the Standard OPI Screen Was Not Built for Oxycodone
Most legacy opiate immunoassays use antibodies raised against morphine. Codeine cross-reacts well with those antibodies because it is chemically close to morphine, so a traditional five-panel "OPI" test performs reasonably well for heroin (which metabolizes to morphine), codeine, and morphine itself. Oxycodone and its metabolite oxymorphone are semi-synthetic opioids with a different molecular structure, and morphine-directed antibodies bind to them poorly or not at all at typical use concentrations. The National Institutes of Health's National Library of Medicine notes that opioid immunoassays can fail to detect a range of related substances, including oxycodone, hydrocodone, hydromorphone, methadone, fentanyl, and buprenorphine, because of this limited cross-reactivity (NIH/NLM, StatPearls, Clinical Drug Testing). In practice, that means a patient or employee could be taking oxycodone in amounts well above a therapeutic dose and still screen negative on a generic OPI cup or dip card.
What an OXY Panel Actually Targets
An OXY panel uses a separate immunoassay built with antibodies specific to oxycodone and oxymorphone, so it screens for those analytes directly rather than hoping for cross-reactivity from a morphine-based test. Federal drug testing regulations codify this distinction. Under 49 CFR 40.85, the cutoff concentration for oxycodone/oxymorphone is set at 100 ng/mL for both the initial immunoassay and the confirmatory test, while the codeine/morphine cutoff is set much higher, at 2,000 ng/mL for both initial and confirmatory testing, and the hydrocodone/hydromorphone cutoff sits at 300 ng/mL initial and 100 ng/mL confirmatory (eCFR, 49 CFR 40.85). Those different cutoffs exist because each analyte pair needs its own assay chemistry tuned to how the drug and its metabolite actually appear in urine.
This split panel approach is relatively recent at the federal level. SAMHSA updated the Mandatory Guidelines for Federal Workplace Drug Testing Programs, effective October 1, 2017, to add testing authority for four semi-synthetic opioids, oxycodone, oxymorphone, hydrocodone, and hydromorphone, after data showed these were among the most frequently misused prescription pain medications (SAMHSA, Mandatory Guidelines Updated to Include Four Semi-Synthetic Opioids). Before that update, a federally compliant opiate panel could miss oxycodone use entirely.
OPI vs OXY: How the Two Panels Compare
| Feature | Standard OPI (Opiate) Panel | OXY (Oxycodone) Panel |
|---|---|---|
| Primary target analytes | Morphine, codeine | Oxycodone, oxymorphone |
| Drug class | Natural opiates (and heroin metabolite 6-AM on expanded panels) | Semi-synthetic opioid and its active metabolite |
| Federal initial test cutoff | 2,000 ng/mL (codeine/morphine) | 100 ng/mL (oxycodone/oxymorphone) |
| Federal confirmatory cutoff | 2,000 ng/mL (codeine/morphine) | 100 ng/mL (oxycodone/oxymorphone) |
| Detects prescription oxycodone (Percocet, OxyContin)? | Unreliable; cross-reactivity is low | Yes, when run as a specific assay |
| Typical use case | General opiate screening, heroin/morphine/codeine focus | Pain management monitoring, treatment program adherence, expanded workplace panels |
Source for federal cutoff concentrations: eCFR, 49 CFR 40.85.
Detection Windows in Urine
Detection windows vary with dose, formulation, frequency of use, hydration, and individual metabolism, so any figure is a general guide rather than a guarantee for a given person. SAMHSA's Treatment Improvement Protocol 63, a clinical reference for medication-assisted treatment providers, lists a urine detection window of roughly 1 to 1.5 days for oxycodone, compared with roughly 1 to 2 days for morphine and codeine on the same reference table (SAMHSA TIP 63, Urine Drug Testing Window of Detection). Because these windows are short and overlapping across opiate and opioid classes, timing alone cannot substitute for using the analyte-specific panel that matches what a program actually needs to monitor.
Why Pain Clinics, Treatment Programs, and Employers Add OXY to Panel Configurations
Pain management practices prescribe oxycodone products routinely and need to confirm patients are taking the medication as directed rather than diverting it, so a panel that actually targets oxycodone is central to an adherence monitoring program. A general OPI screen that misses oxycodone gives a false sense of compliance. Configurations built for this setting are available in ASC's pain management and pain clinic drug testing collection.
Addiction treatment and recovery programs face a similar problem from the other direction: they need to distinguish prescribed medication-assisted treatment from unauthorized opioid use, and a panel that cannot see oxycodone leaves a blind spot in that picture. Programs building out a panel configuration for this purpose can review ASC's addiction recovery drug and alcohol testing collection.
Employers, meanwhile, choose panel configurations based on their workforce risk and any regulatory framework that applies to them. Since the 2017 Mandatory Guidelines update, federal workplace testing programs have had the authority to include the four semi-synthetic opioids alongside traditional opiates (SAMHSA, cited above), and many private-sector employers configure non-DOT panels the same way to close the same detection gap. Employers evaluating options can start from ASC's broader drug of abuse test kits collection and select a configuration that includes an OXY target rather than relying on OPI alone.
Confirmation Testing and MRO Review of Prescriptions
A non-negative screening result on either an OPI or OXY panel is not a final finding. It is a screen, and federally compliant programs require confirmation by gas chromatography/mass spectrometry or liquid chromatography tandem mass spectrometry before any result is reported as positive. Laboratories and clinics building out confirmation capability can review ASC's drug test kits for laboratories collection.
For DOT-regulated and federal workplace testing, a confirmed positive for a semi-synthetic opioid still goes through Medical Review Officer review before it becomes a reportable result. Under 49 CFR 40.137, the MRO must verify a confirmed positive for semi-synthetic opioids, including oxycodone and oxymorphone, as positive unless the employee presents a legitimate medical explanation, such as a legally valid prescription consistent with the Controlled Substances Act. The employee carries the burden of presenting that evidence at the verification interview, and the MRO may extend the timeline by up to five days if there is a reasonable basis to believe supporting documentation is coming (eCFR, 49 CFR 40.137). A valid prescription, once verified, results in the test being reported as negative rather than positive.
Building an Oxycodone-Aware Panel Configuration
Programs that need to see oxycodone use should not assume a standard 5-panel or general opiate cup already covers it. The practical fix is selecting a multi-panel cup or dip card that lists OXY as a distinct target alongside OPI, MOP, or MTD, depending on what else the program needs to monitor. ASC stocks configurable options across its drug testing cups and drug test dip card collections, so buyers can match the panel to the population being tested rather than defaulting to a generic configuration that was never designed to catch semi-synthetic opioids.
Frequently Asked Questions
Does oxycodone show up on a standard drug test?
Not reliably. A standard opiate (OPI) immunoassay is built around antibodies that target morphine and codeine, and it has limited cross-reactivity with oxycodone. A screen specifically labeled OXY, or a mass spectrometry confirmation test, is needed to detect oxycodone with confidence.
What is the difference between an OPI panel and an OXY panel?
An OPI panel targets natural opiates, primarily morphine and codeine. An OXY panel uses a separate immunoassay built to target oxycodone and its metabolite oxymorphone directly, which are semi-synthetic opioids that OPI antibodies do not reliably detect.
What cutoff level is used for oxycodone on a drug test?
Under federal regulation 49 CFR 40.85, the cutoff concentration for oxycodone/oxymorphone is 100 ng/mL for both the initial screening test and the confirmatory test. That is far lower than the 2,000 ng/mL cutoff used for codeine/morphine on a standard opiate panel.
Can a prescription for oxycodone cause a positive drug test?
Yes, and that is expected. Under 49 CFR 40.137, a Medical Review Officer must verify a confirmed positive for a semi-synthetic opioid as positive unless the individual presents a legitimate medical explanation, such as a valid prescription consistent with the Controlled Substances Act. Once verified, a legitimate prescription results in the test being reported as negative.
Related reading
This article is for general educational purposes and does not constitute medical, legal, or regulatory advice. Drug and alcohol test screening devices provide presumptive results only; any non-negative screen requires laboratory confirmation, and any prescription-related explanation should be reviewed through a qualified Medical Review Officer. Testing programs should consult applicable federal, state, and local regulations and their own legal counsel when designing a testing policy.
